HUMAN GENOME , DENDREON 2009...enter CombinatoRx (CRXX) 2010-2011 - 500 Beiträge pro Seite
eröffnet am 17.05.10 14:09:35 von
neuester Beitrag 20.09.10 17:14:50 von
neuester Beitrag 20.09.10 17:14:50 von
Beiträge: 28
ID: 1.157.853
ID: 1.157.853
Aufrufe heute: 2
Gesamt: 2.680
Gesamt: 2.680
Aktive User: 0
ISIN: US29428P1075 · WKN: A117U3 · Symbol: EPRSQ
0,0001
USD
+9.900,00 %
+0,0001 USD
Letzter Kurs 22.04.24 Nasdaq OTC
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 2,2999 | +25,68 | |
| 1,9200 | +23,87 | |
| 3,2000 | +22,84 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,4000 | -11,69 | |
| 0,6605 | -12,11 | |
| 13,270 | -12,64 | |
| 3,1350 | -17,45 | |
| 0,5121 | -30,80 |
FeedbackHuman Genome (HGSI)
Dendreon (DNDN)
CombinatoRx(CRXX)...(Ein stetigen Anstieg sollte "baldigst" losgehen
)Pipeline & Eckdaten:
Marktkapital.159,96 Mio. USD
89 Mio. Stücke
700 Mio USD Übernahmeangebot wurde vor kürzem abgelenht...Kurs 4heute in Germany 1,40€ ..watch this space
By the way, direkt von CRXX's jüngste 10Q (erst letzte Woche Freitag Publik gemacht 
)
Straight from the 10Q ... it is EXCELLENT NEWS!!!
$7,664,000 Covidien Q2 (billed 31 Mar 2010)
+ Novartis
+ Amgen
+ Fovea
+ Other grants and collaborations
--------------
8-10M in income is a reasonable target for Q2
....................
Q3
First royalty payments (9%) Covidien
+ Billed work for Exalgo Q2 Covidien
+ Novartis
+ Amgen
+ Fovea/Sanofi Aventis
+ Other grants and collaborations
Ein paar sehr gute Namen dabei
, mit ein bereits zugelassen Medikament -(man kennt die "FDA Anforderungen" innen & auswendig )und die Listen der interessenten wird täglich länger
40 MIO USD Milestone von Coviden war auch im Q3 Report zu sehen...ein Biotech unter 10USD der schon Geld verdient, ja, sowas gibts noch
) Straight from the 10Q ... it is EXCELLENT NEWS!!!
$7,664,000 Covidien Q2 (billed 31 Mar 2010)
+ Novartis
+ Amgen
+ Fovea
+ Other grants and collaborations
--------------
8-10M in income is a reasonable target for Q2
....................
Q3
First royalty payments (9%) Covidien
+ Billed work for Exalgo Q2 Covidien
+ Novartis
+ Amgen
+ Fovea/Sanofi Aventis
+ Other grants and collaborations
Ein paar sehr gute Namen dabei
, mit ein bereits zugelassen Medikament -(man kennt die "FDA Anforderungen" innen & auswendig )und die Listen der interessenten wird täglich länger40 MIO USD Milestone von Coviden war auch im Q3 Report zu sehen...ein Biotech unter 10USD der schon Geld verdient, ja, sowas gibts noch
Antwort auf Beitrag Nr.: 39.531.877 von Uptick08 am 17.05.10 14:18:08Schreibst Du jetzt schon wieder auf Englisch, nimm doch bitte Rücksicht auf unseren Freund G1! 
Antwort auf Beitrag Nr.: 39.532.063 von EPB am 17.05.10 14:49:04EPB, du hast mich ja erwischt 
...ich gelobe Besserung
...ich gelobe Besserung
Daß jetzt dieser pusherthread aufgemacht wird, ist ein gutes Zeichen dafür, daß man bei crxx sehr gelassen hinschauen sollte, was jetzt passiert...
Trading Spotlight
Antwort auf Beitrag Nr.: 39.532.063 von EPB am 17.05.10 14:49:04(By special request for users not yet named) 
CRXX's Mark Corrigan – President & CEO & seeking Alpha interview 2010....
"I joined CombinatoRx because I see the potential to build a really great biopharmaceutical company, delivering breakthrough products to patients and physicians. As a former Neuromed Board member, I'm very familiar with the merged pipeline opportunities and platform assets that reside within the new CombinatoRx.
We have a number of wholly owned assets that, if managed correctly, could be significant contributors to our future success, including a number of potential product opportunities, true state-of-the-art cell-based drug discovery technologies and proven drug development and regulatory expertise."
"We managed the FDA approval of Exalgo, which triggered a $40 million milestone payment, entered into a significant research alliance with Novartis, reported positive Phase II clinical data on Synavive in knee osteoarthritis, and improved the financial terms in our Fovea product development collaboration with Sanofi-Aventis."
"Second is a clear demonstration of our considerable product development expertise. These capabilities reside within our team here at CombinatoRx and will be applied to the many promising drug candidates in our product pipeline going forward."
"We have brought together two state-of-the-art cell-based drug discovery technologies, our Selective Ion channel modulation platform and the cHTS drug discovery technology here in Cambridge, as well as our proven drug development expertise, which we will apply to product assets in our portfolio going forward. These accomplishments over the past year position CombinatoRx to thrive through the long term."
"After a thorough review of our pipeline assets, development expertise, unmet medical needs, and available resources, we have made the strategic decision to focus our R&D efforts in the core therapeutic areas of pain and inflammation. As a result of this driving mission to become a great pain and inflammation company, we have prioritized our product pipeline to focus our time and resources on advancing those internal programs that best fit that profile including Synavive for the treatment of immuno-inflammatory diseases and our N-Type and T-Type calcium channel blockers which have the potential to be a new class of therapeutics for the treatment of chronic pain."
"During the remainder of 2010, our product development goals include; first, conducting the earlier-stage work necessary to advance the development of Synavive for the treatment of osteoarthritis. I have reviewed the data on this program and in my opinion, Synavive could be an excellent medicine, but it needs closer evaluation over the next few months."
"Secondly, we plan to advance an N-Type lead program from our Ion channel modulation platform into development. We are world leaders in the field of Ion channel modulation with a strong patent portfolio and an experienced Ion channel research team focused on calcium and sodium channel pain blockers."
"Thirdly, we will continue to apply our state-of-the-art drug discovery technologies to discover new pain and inflammation product candidates from our internal portfolio, utilizing our Selective Ion channel modulation platform and the cHTS drug discovery technology."
"I realize you are probably anxious to hear more about our development plans going forward and we will be in a better position to further articulate our actions in this regard as our evaluation continues.
On the business side, our goals for 2010 include continuing to seek an additional revenue-generating research and technology collaboration for our drug discovery platform such as the Novartis alliance, and maintaining financial strength with sufficient resources to fund operations into 2014. Justin will speak more about this in his remarks now."
http://seekingalpha.com/article/195574-combinatorx-inc-q4-20…
CRXX's Mark Corrigan – President & CEO & seeking Alpha interview 2010....
"I joined CombinatoRx because I see the potential to build a really great biopharmaceutical company, delivering breakthrough products to patients and physicians. As a former Neuromed Board member, I'm very familiar with the merged pipeline opportunities and platform assets that reside within the new CombinatoRx.
We have a number of wholly owned assets that, if managed correctly, could be significant contributors to our future success, including a number of potential product opportunities, true state-of-the-art cell-based drug discovery technologies and proven drug development and regulatory expertise."
"We managed the FDA approval of Exalgo, which triggered a $40 million milestone payment, entered into a significant research alliance with Novartis, reported positive Phase II clinical data on Synavive in knee osteoarthritis, and improved the financial terms in our Fovea product development collaboration with Sanofi-Aventis."
"Second is a clear demonstration of our considerable product development expertise. These capabilities reside within our team here at CombinatoRx and will be applied to the many promising drug candidates in our product pipeline going forward."
"We have brought together two state-of-the-art cell-based drug discovery technologies, our Selective Ion channel modulation platform and the cHTS drug discovery technology here in Cambridge, as well as our proven drug development expertise, which we will apply to product assets in our portfolio going forward. These accomplishments over the past year position CombinatoRx to thrive through the long term."
"After a thorough review of our pipeline assets, development expertise, unmet medical needs, and available resources, we have made the strategic decision to focus our R&D efforts in the core therapeutic areas of pain and inflammation. As a result of this driving mission to become a great pain and inflammation company, we have prioritized our product pipeline to focus our time and resources on advancing those internal programs that best fit that profile including Synavive for the treatment of immuno-inflammatory diseases and our N-Type and T-Type calcium channel blockers which have the potential to be a new class of therapeutics for the treatment of chronic pain."
"During the remainder of 2010, our product development goals include; first, conducting the earlier-stage work necessary to advance the development of Synavive for the treatment of osteoarthritis. I have reviewed the data on this program and in my opinion, Synavive could be an excellent medicine, but it needs closer evaluation over the next few months."
"Secondly, we plan to advance an N-Type lead program from our Ion channel modulation platform into development. We are world leaders in the field of Ion channel modulation with a strong patent portfolio and an experienced Ion channel research team focused on calcium and sodium channel pain blockers."
"Thirdly, we will continue to apply our state-of-the-art drug discovery technologies to discover new pain and inflammation product candidates from our internal portfolio, utilizing our Selective Ion channel modulation platform and the cHTS drug discovery technology."
"I realize you are probably anxious to hear more about our development plans going forward and we will be in a better position to further articulate our actions in this regard as our evaluation continues.
On the business side, our goals for 2010 include continuing to seek an additional revenue-generating research and technology collaboration for our drug discovery platform such as the Novartis alliance, and maintaining financial strength with sufficient resources to fund operations into 2014. Justin will speak more about this in his remarks now."
http://seekingalpha.com/article/195574-combinatorx-inc-q4-20…
Antwort auf Beitrag Nr.: 39.532.768 von kontaktfenster am 17.05.10 16:05:58Wie defeniert mann Pushing überhaupt? Wenn ich 'FÜR MEINE BEGRIFFE' Neuigkeiten/Chancen am Markt entdecke, schreibe ich dieses gerne nieder...
...und wenn du der Inhalt meiner Posting als "Push" verstehts (anstatt der Platform für eine Meinungsaustausch bzw. als Informationsforum zu nützen) dann wurde ich dich höfflichst drum bitten hier keine weitere nutzlose kommentare(völlig Bezugsfreie) hier nieder zu schreiben
...und wenn du der Inhalt meiner Posting als "Push" verstehts (anstatt der Platform für eine Meinungsaustausch bzw. als Informationsforum zu nützen) dann wurde ich dich höfflichst drum bitten hier keine weitere nutzlose kommentare(völlig Bezugsfreie) hier nieder zu schreiben
Antwort auf Beitrag Nr.: 39.532.868 von Uptick08 am 17.05.10 16:16:06hallo Uptick,
habe den Wert auch auf meiner watchlist - dank eines Bio-experten
Bin am überlegen einzusteigen...
Was hälst du von AEZS?
gruß
af
habe den Wert auch auf meiner watchlist - dank eines Bio-experten
Bin am überlegen einzusteigen...
Was hälst du von AEZS?
gruß
af
Antwort auf Beitrag Nr.: 39.531.826 von Uptick08 am 17.05.10 14:09:35hi,
wer wollte die kaufen ?? hast du dafür nen link???
wer wollte die kaufen ?? hast du dafür nen link???
Antwort auf Beitrag Nr.: 39.532.868 von Uptick08 am 17.05.10 16:16:06da hat wohl jemand ein flattriges nervenkostüm
hab den wert gerade von meiner wl verbannt, aber jetzt wieder draufgenommen
Mal schauen, was der Laden hermacht.
hab den wert gerade von meiner wl verbannt, aber jetzt wieder draufgenommen
Mal schauen, was der Laden hermacht.
Antwort auf Beitrag Nr.: 39.534.106 von vanillamilkshake am 17.05.10 18:49:04CRXX konnte seit Februar ja schon etwas zulegen.
hab noch RGN, AGEN und LTUS aus der Branche auf der WL.
BSMD is die letzten Tage auch gut abgegangen, dank Übernahme:
hab noch RGN, AGEN und LTUS aus der Branche auf der WL.
BSMD is die letzten Tage auch gut abgegangen, dank Übernahme:
Antwort auf Beitrag Nr.: 39.533.992 von KnigRollo am 17.05.10 18:35:42ja, ein Quellennachweis wäre schön! Der Rest überzeugt mich.
Antwort auf Beitrag Nr.: 39.533.427 von againstfotsch am 17.05.10 17:23:35Moin againstfotsch! "Was hälst du von AEZS?"
Kannte ich gar nicht mal...aber das Chartbild (Zehntage bis Dreimonate)sieht recht "Gesund" aus viel Glück dabei!
@ KnigRollo "wer wollte die kaufen ?? hast du dafür nen link???"
"Covidien" (sie haben den Lizenz für Exalgo erworben (Das zugelassene Schmerzmedikament)-
Description Covidien is a leading manufacturer of medical devices and supplies, diagnostic imaging agents and pharmaceuticals, with 2008 revenue of nearly $10 billion and industry-leading profit margins. It has more than 41, 000 employees worldwide in 59 countries, with products sold in over 140 countries and spent nearly $350 million in R&D during 2008 alone, with that amount expected to increase in 2009. Its business segments include Medical Devices, Pharmaceuticals and Medical Supplies.
Habe leider kein Link dazu, die Informationen standen bei Yahoo im Board (war allerdings exzellent dokumentiert & sehr fundiert dargestellt)finde ich leider nicht mehr beim ganzen "gewühl" der mittlerweile dort stattfindet
Coviden könnte CRXX jedenfalls aus der Portokasse zukaufen wenn es "Hart auf Hart" kommt ...ich hoffe insgeheim auf ein Bieterwettbewerb zum späteren Zeitpunkt
Nun wird allerdings dort vermutet das seit CRXX vier CHs Patente kurzfrisitig angemeldet hat (seit Anfang April) das der Firma für Amgen mittlerweile sogar von Interesse sein könnte(das ganze natürlich ohne Gewähr)
(OHN
Kannte ich gar nicht mal...aber das Chartbild (Zehntage bis Dreimonate)sieht recht "Gesund" aus viel Glück dabei!
@ KnigRollo "wer wollte die kaufen ?? hast du dafür nen link???"
"Covidien" (sie haben den Lizenz für Exalgo erworben (Das zugelassene Schmerzmedikament)-
Description Covidien is a leading manufacturer of medical devices and supplies, diagnostic imaging agents and pharmaceuticals, with 2008 revenue of nearly $10 billion and industry-leading profit margins. It has more than 41, 000 employees worldwide in 59 countries, with products sold in over 140 countries and spent nearly $350 million in R&D during 2008 alone, with that amount expected to increase in 2009. Its business segments include Medical Devices, Pharmaceuticals and Medical Supplies.
Habe leider kein Link dazu, die Informationen standen bei Yahoo im Board (war allerdings exzellent dokumentiert & sehr fundiert dargestellt)finde ich leider nicht mehr beim ganzen "gewühl" der mittlerweile dort stattfindet
Coviden könnte CRXX jedenfalls aus der Portokasse zukaufen wenn es "Hart auf Hart" kommt ...ich hoffe insgeheim auf ein Bieterwettbewerb zum späteren Zeitpunkt Nun wird allerdings dort vermutet das seit CRXX vier CHs Patente kurzfrisitig angemeldet hat (seit Anfang April) das der Firma für Amgen mittlerweile sogar von Interesse sein könnte(das ganze natürlich ohne Gewähr)
(OHN
Hier die neusten cHTS Patent Anmeldung von 4 Mai...aber bisher nicht von CRXX Publik gemacht, wieso frage ich mich?????
http://www.freepatentsonline.com/7709495
{United States Patent US7709495
CombinatoRx, 4 May 2010 patent granted, discovered that Ibudalist -
"According to the invention, any immunoinflammatory disorder may be treated by administration of an effective amount of an ibudalist or analog thereof, either alone or in combination with one or more additional compounds."
Könnte wirklich big werden (4th Patent 2010) - "combination" = cHTS Chalice!!!}
Nun ja, we will see in time...
http://www.freepatentsonline.com/7709495
{United States Patent US7709495
CombinatoRx, 4 May 2010 patent granted, discovered that Ibudalist -
"According to the invention, any immunoinflammatory disorder may be treated by administration of an effective amount of an ibudalist or analog thereof, either alone or in combination with one or more additional compounds."
Könnte wirklich big werden (4th Patent 2010) - "combination" = cHTS Chalice!!!}
Nun ja, we will see in time...
Antwort auf Beitrag Nr.: 39.537.971 von Uptick08 am 18.05.10 11:47:18Sorry, hier der Link nochmal
http://www.freepatentsonline.com/7709495.pdf
http://www.freepatentsonline.com/7709495.pdf
Auch mal lesenswert zwischendurch ....
"Why Traders Are Salivating - Outlooks for UXG, CRXX, and SWHC..."
Back on May 3rd, after CombinatoRx, Incorporated (NASDAQ:CRXX) had popped above a resistance line at $1.51 a little too bullishly for its own good, I specifically made the point that potential new buyers would want to wait to see if CRXX could actually establish a base above $1.51 before diving in. Well, good news.... this small cap has indeed used that former resistance line at $1.51 as a support line; it's safe to wade into the waters.
And on a side note, CombinatoRx shares are particularly well-positioned for a move, having gone through a consolidation phase between February and April. All of its key moving averages converged in late March, which will ultimately set up a big divergence....periods of low volatility are followed by periods of high volatility, and vise versa.
"Why Traders Are Salivating - Outlooks for UXG, CRXX, and SWHC..."
Back on May 3rd, after CombinatoRx, Incorporated (NASDAQ:CRXX) had popped above a resistance line at $1.51 a little too bullishly for its own good, I specifically made the point that potential new buyers would want to wait to see if CRXX could actually establish a base above $1.51 before diving in. Well, good news.... this small cap has indeed used that former resistance line at $1.51 as a support line; it's safe to wade into the waters.
And on a side note, CombinatoRx shares are particularly well-positioned for a move, having gone through a consolidation phase between February and April. All of its key moving averages converged in late March, which will ultimately set up a big divergence....periods of low volatility are followed by periods of high volatility, and vise versa.
Low-Profile Stocks for High Returns....
http://www.fool.com/investing/small-cap/2010/06/01/low-profi…
Nun ja, time will tell
http://www.fool.com/investing/small-cap/2010/06/01/low-profi…
Nun ja, time will tell
Asco Meeting geht weiter ab Morgen statside...
http://chicago2010.asco.org/AttendeeInformation/ExhibitorLis…
Monday at 5pm, Corrigan (CEO CRXX)will report: "We have identified two compounds that are:
POTENT PAIN KILLERS
ORAL MEDICATIONS
EFFECTIVE AS N-TYPE CALCIUM CHANNEL BLOCKER
These compounds are the >>>first-ever oral compounds<<< shown to be efficacious potent calcium channel blockers in both N-Type and L-Type. This discovery is published and all patents are filed. If successful in clinical studies, these compounds represent the first-ever pain medications will forever change how we treat pain. In terms of value, they are each worth billions because their potential application is enormous."
http://www(dot)snutchlab.msl.ubc.ca/publications/pdfu pload/…
Alle potentielle Partner werden an der Asco Konferenz/Treffen teilnehmen (sehr gute Platform für Corrigan-"falls" er Tacheles reden will )
http://chicago2010.asco.org/AttendeeInformation/ExhibitorLis…
Monday at 5pm, Corrigan (CEO CRXX)will report: "We have identified two compounds that are:
POTENT PAIN KILLERS
ORAL MEDICATIONS
EFFECTIVE AS N-TYPE CALCIUM CHANNEL BLOCKER
These compounds are the >>>first-ever oral compounds<<< shown to be efficacious potent calcium channel blockers in both N-Type and L-Type. This discovery is published and all patents are filed. If successful in clinical studies, these compounds represent the first-ever pain medications will forever change how we treat pain. In terms of value, they are each worth billions because their potential application is enormous."
http://www(dot)snutchlab.msl.ubc.ca/publications/pdfu pload/…
Alle potentielle Partner werden an der Asco Konferenz/Treffen teilnehmen (sehr gute Platform für Corrigan-"falls" er Tacheles reden will
)
Antwort auf Beitrag Nr.: 39.637.938 von Uptick08 am 06.06.10 10:59:03<<"IF">> the trend is truly your friend...
...dann sollte CRXX's Asco-Auftritt weitere Benzin im Feuer giessen
Mal auf die Zunge zergehen lassen:
"If successful in clinical studies, these compounds represent the first-ever pain medications will forever change how we treat pain. In terms of value, "they are each worth billions" because their potential application is enormous."
Naja, mal schauen, die Aktie notiert um die 1,20€ zurzeit, and counting
...dann sollte CRXX's Asco-Auftritt weitere Benzin im Feuer giessen
Mal auf die Zunge zergehen lassen:
"If successful in clinical studies, these compounds represent the first-ever pain medications will forever change how we treat pain. In terms of value, "they are each worth billions" because their potential application is enormous."
Naja, mal schauen, die Aktie notiert um die 1,20€ zurzeit, and counting
Der Preistreiber schlechthin...
http://finance.yahoo.com/news/CombinatoRx-Set-to-Join-the-bw…
...der Handelsvolumina wird (meiner bescheidener Meinung nach) stetig anwachsen bis ende Sept/Okt ab jetzt
(Wegen der nun anstehende "Fondsammelsaison")
http://finance.yahoo.com/news/CombinatoRx-Set-to-Join-the-bw…
...der Handelsvolumina wird (meiner bescheidener Meinung nach) stetig anwachsen bis ende Sept/Okt ab jetzt
(Wegen der nun anstehende "Fondsammelsaison")
Antwort auf Beitrag Nr.: 39.697.658 von Uptick08 am 17.06.10 13:24:08Der Artikel wird irgendwannmal bald nicht mehr lesbar sein via link, von daher der print version (für die Ewigkeit) anbei...
CombinatoRx Set to Join the Russell 3000 Index
Press Release Source: CombinatoRx, Incorporated On Tuesday June 15, 2010, 4:01 pm EDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX - News) announced today that it is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, according to a preliminary list of additions posted June 11 on www.russell.com. CombinatoRx will likely also be included in the Russell 2000, a subset of the Russell 3000 index for 2,000 of the smaller companies based on market capitalization. Initial inclusion in the Russell indexes may lead to an increase in trading volume when investment funds that track the index add CombinatoRx shares to their portfolios.
Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.
The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in assets currently are benchmarked to them. These investment tools originated from Russell’s multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.
Total returns data for the Russell 3000 and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.
About Russell:
Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has $179 billion in assets under management as of March 31, 2010, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.
About CombinatoRx
CombinatoRx, Incorporated (CRXX) develops novel drug candidates with a focus on the treatment of pain and inflammation. The company applies its combination drug discovery capabilities and its selective ion-channel modulation platform to generate innovative therapeutics. To learn more about CombinatoRx, please visit www.combinatorx.com.
CombinatoRx Set to Join the Russell 3000 Index
Press Release Source: CombinatoRx, Incorporated On Tuesday June 15, 2010, 4:01 pm EDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX - News) announced today that it is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, according to a preliminary list of additions posted June 11 on www.russell.com. CombinatoRx will likely also be included in the Russell 2000, a subset of the Russell 3000 index for 2,000 of the smaller companies based on market capitalization. Initial inclusion in the Russell indexes may lead to an increase in trading volume when investment funds that track the index add CombinatoRx shares to their portfolios.
Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.
The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.
An industry-leading $3.9 trillion in assets currently are benchmarked to them. These investment tools originated from Russell’s multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.Total returns data for the Russell 3000 and other Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.
About Russell:
Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has $179 billion in assets under management as of March 31, 2010, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.
About CombinatoRx
CombinatoRx, Incorporated (CRXX) develops novel drug candidates with a focus on the treatment of pain and inflammation. The company applies its combination drug discovery capabilities and its selective ion-channel modulation platform to generate innovative therapeutics. To learn more about CombinatoRx, please visit www.combinatorx.com.
Kürze re-cap/Zusammenfassung im sachen CRXX:
MK: 145,03 Mio. USD
Aktien Freefloat: 89 Mio
Cash on Hand: 65 Mio USD
Pipeline: Vier potentielle Produkte(Eins davon bereits zugelassen mit milestone income)
Markt Potential: Zwei Oral einzunehmende Produkte, 1 Mrd USD Markttiefe/Potential je Schmerz linie (der dreifacheumsatz wäre auch im Rahmen des möglichen im falle des "Oraleinnamhe")
But as always, we will see in time
MK: 145,03 Mio. USD
Aktien Freefloat: 89 Mio
Cash on Hand: 65 Mio USD
Pipeline: Vier potentielle Produkte(Eins davon bereits zugelassen mit milestone income)
Markt Potential: Zwei Oral einzunehmende Produkte, 1 Mrd USD Markttiefe/Potential je Schmerz linie (der dreifacheumsatz wäre auch im Rahmen des möglichen im falle des "Oraleinnamhe")
But as always, we will see in time
Lesenswert....
http://www.piribo.com/publications/diseases_conditions/addic…
Examines the market for addiction pharmacotherapies currently estimated at US$2 billion but forecast to increase 41% CAGR to US$2.9 billion by 2012.
REPORT HIGHLIGHTS AND KEY FINDINGS
# The current market for addiction disorders is valued at US$2 billion, which is forecast to increase 41% CAGR to US$2.9 billion by 2012
# Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
# Review of epidemiological, aetiological, and demographic data for addiction disorders
# Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
# Sales estimates (US$) to 2012 for major therapy areas
# Strategic insights for life-cycle optimization and product development
# Critical evaluation of leading addiction pharmacotherapies
# Emerging markets identified and sector analysis
# Trend analysis of industry events and activities over past 2 years
# Detailed R&D themes and clusters by addiction area
# Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
# High revenue-yielding prospects identified with projected sales estimations
# R&D pipeline positioning for novel candidates
# Market insights for product development and drug promotion
http://www.piribo.com/publications/diseases_conditions/addic…
Examines the market for addiction pharmacotherapies currently estimated at US$2 billion but forecast to increase 41% CAGR to US$2.9 billion by 2012.
REPORT HIGHLIGHTS AND KEY FINDINGS
# The current market for addiction disorders is valued at US$2 billion, which is forecast to increase 41% CAGR to US$2.9 billion by 2012
# Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
# Review of epidemiological, aetiological, and demographic data for addiction disorders
# Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
# Sales estimates (US$) to 2012 for major therapy areas
# Strategic insights for life-cycle optimization and product development
# Critical evaluation of leading addiction pharmacotherapies
# Emerging markets identified and sector analysis
# Trend analysis of industry events and activities over past 2 years
# Detailed R&D themes and clusters by addiction area
# Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
# High revenue-yielding prospects identified with projected sales estimations
# R&D pipeline positioning for novel candidates
# Market insights for product development and drug promotion
One last thing...$2,5USD kurzfristziel/$1,16 resistance
I don't know if this is just something I had never noticed about CombinatoRx, Incorporated (NASDAQ:CRXX) before, or if it became apparent only recently, and I haven't looked at a chart of CRXX. Whatever the case though, I see it now - this small cap is now in a bullish (albeit volatile) trading channel, and is now out of a bearish trading channel from the latter half of last year.
It's all framed in blue below. CombinatoRx shares popped out of their descending (and converging) wedge in January, and formed a bullish (& diverging) channel since then. In fact, this small cap just pushed off the lower side of that zone a few days ago, meaning now is a better-than-average entry window. You can also see there's an important support/resistance line (black) at $1.16.
http://de_de.www.smallcapnetwork.com/Almost-In-Pictures-Look…
I don't know if this is just something I had never noticed about CombinatoRx, Incorporated (NASDAQ:CRXX) before, or if it became apparent only recently, and I haven't looked at a chart of CRXX. Whatever the case though, I see it now - this small cap is now in a bullish (albeit volatile) trading channel, and is now out of a bearish trading channel from the latter half of last year.
It's all framed in blue below. CombinatoRx shares popped out of their descending (and converging) wedge in January, and formed a bullish (& diverging) channel since then. In fact, this small cap just pushed off the lower side of that zone a few days ago, meaning now is a better-than-average entry window. You can also see there's an important support/resistance line (black) at $1.16.
http://de_de.www.smallcapnetwork.com/Almost-In-Pictures-Look…
Stuttgart...
Nasdaq...
Watch this space...der anfallende Russel-Volumina wird "langsam aber sicher" ersichtlich im Chartverlauf
Bei weiteren Übernameangebote bzw. Pipeline/Milestone Erfolg, sind wir ratz fatz bei
5$ plus...und jeder von uns weiss ab wann der Ami-Fonds solche "small caps" mal beaugt im sachen "Frühaufname"
Looking good soweit
Big news im anmarsch.......SYNAVIVE patent info from Lasar!!!
SYNAVIVE Newsflash: Euro Patent Today!!! 8-Jul-10 08:11 pm I give two references:
Delete the "(dot)" and substitute with a period ( www. )
http://www(dot)freepatentsonline.com/EP2203174A1.html
and
http://www(dot)faqs.org/patents/app/20090075955
The first reference gives the 7.7.10 date
The second reference gives the patent info
This patent is the works!!! HUGE!!! ENORMOUS!!!
"BACKGROUND OF THE INVENTION
[0002]The combination of prednisolone and dipyridamole is an orally available synergistic drug candidate in Phase 2 clinical development for the treatment of immunoinflammatory disorders. A synergistic drug includes two compounds that are designed to act synergistically through multiple pathways to provide a therapeutic effect which neither component administered alone and at the same dosing levels can achieve. The combination of prednisolone with dipyridamole was designed to selectively amplify certain elements of prednisolone's anti-inflammatory and immunomodulatory activities, without replicating steroid side effects.
[0003]Proper formulation is essential to maximize the therapeutic benefit of a synergistic drug combination.
SUMMARY OF THE INVENTION
[0004]The invention provides methods, compositions, and kits for administering dipyridamole in combination with a corticosteroid. This combination is useful for the treatment of immunoinflammatory disorders."
SYNABISCUIT IS BACK!!! AND SHE IS SO BEAUTIFUL!!!
IMO, this could signal osteoarthritis hand in EUROPE.
Sentiment : Strong Buy
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
...SYNAVIVE patent info from Lasar!!!SYNAVIVE Newsflash: Euro Patent Today!!! 8-Jul-10 08:11 pm I give two references:
Delete the "(dot)" and substitute with a period ( www. )
http://www(dot)freepatentsonline.com/EP2203174A1.html
and
http://www(dot)faqs.org/patents/app/20090075955
The first reference gives the 7.7.10 date
The second reference gives the patent info
This patent is the works!!! HUGE!!! ENORMOUS!!!
"BACKGROUND OF THE INVENTION
[0002]The combination of prednisolone and dipyridamole is an orally available synergistic drug candidate in Phase 2 clinical development for the treatment of immunoinflammatory disorders. A synergistic drug includes two compounds that are designed to act synergistically through multiple pathways to provide a therapeutic effect which neither component administered alone and at the same dosing levels can achieve. The combination of prednisolone with dipyridamole was designed to selectively amplify certain elements of prednisolone's anti-inflammatory and immunomodulatory activities, without replicating steroid side effects.
[0003]Proper formulation is essential to maximize the therapeutic benefit of a synergistic drug combination.
SUMMARY OF THE INVENTION
[0004]The invention provides methods, compositions, and kits for administering dipyridamole in combination with a corticosteroid. This combination is useful for the treatment of immunoinflammatory disorders."
SYNABISCUIT IS BACK!!! AND SHE IS SO BEAUTIFUL!!!
IMO, this could signal osteoarthritis hand in EUROPE.
Sentiment : Strong Buy
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
War lange nicht mehr im Forum...
Also, dementsprechend 'formhalber' folgender Infos, CRXX ist unmfirmiert worden in Zalicius(ZLCS) ein Schmerz Bekämpfungsfirma (mit zwei bereits zugelassenen Schmerzmedikamente in den USA)
CombinatoRx Changes Company Name to Zalicus Inc.
http://finance.yahoo.com/news/CombinatoRx-Changes-Company-bw…
About the Zalicus Pipeline
Zalicus focuses its internal drug development efforts on pain and immuno-inflammatory diseases. Our pipeline for pain includes Exalgo™ (hydromorphone HCl) extended-release tablets (marketed by Covidien), for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time and our Ion channel program, which is advancing a lead candidate into clinical development for pain. Our pipeline for immuno-inflammatory diseases includes Synavive™, in Phase 2 development for rheumatoid arthritis and Prednisporin™ (FOV1101; licensed to Sanofi-Aventis/Fovea), a topical ocular drug candidate in Phase 2b clinical development for persistent allergic conjunctivitis that Zalicus exclusively licensed to Fovea Pharmaceuticals SA, a division of Sanofi Aventis.
more to come...
Also, dementsprechend 'formhalber' folgender Infos, CRXX ist unmfirmiert worden in Zalicius(ZLCS) ein Schmerz Bekämpfungsfirma (mit zwei bereits zugelassenen Schmerzmedikamente in den USA)
CombinatoRx Changes Company Name to Zalicus Inc.
http://finance.yahoo.com/news/CombinatoRx-Changes-Company-bw…
About the Zalicus Pipeline
Zalicus focuses its internal drug development efforts on pain and immuno-inflammatory diseases. Our pipeline for pain includes Exalgo™ (hydromorphone HCl) extended-release tablets (marketed by Covidien), for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time and our Ion channel program, which is advancing a lead candidate into clinical development for pain. Our pipeline for immuno-inflammatory diseases includes Synavive™, in Phase 2 development for rheumatoid arthritis and Prednisporin™ (FOV1101; licensed to Sanofi-Aventis/Fovea), a topical ocular drug candidate in Phase 2b clinical development for persistent allergic conjunctivitis that Zalicus exclusively licensed to Fovea Pharmaceuticals SA, a division of Sanofi Aventis.
more to come...
So schnell geht das...(umfirmiert am 16.08)
Zalicus Inc. (ZLCS) President and CEO to Ring The NASDAQ Stock Market Closing Bell
http://finance.yahoo.com/news/Zalicus-Inc-ZLCS-President-pz-…
Hier das gesamte 'Zalicus Data' auf einem Schlag:
http://quotes.nasdaq.com/asp/SummaryQuote.asp?symbol=ZLCS&se…
Zalicus Inc. (ZLCS) President and CEO to Ring The NASDAQ Stock Market Closing Bell
http://finance.yahoo.com/news/Zalicus-Inc-ZLCS-President-pz-…
Hier das gesamte 'Zalicus Data' auf einem Schlag:
http://quotes.nasdaq.com/asp/SummaryQuote.asp?symbol=ZLCS&se…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,22 | |
| -0,39 | |
| +0,40 | |
| -3,82 | |
| 0,00 | |
| 0,00 | |
| +0,72 | |
| -8,66 | |
| -2,16 | |
| +1,14 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 239 | ||
| 83 | ||
| 82 | ||
| 77 | ||
| 68 | ||
| 55 | ||
| 49 | ||
| 47 | ||
| 34 | ||
| 34 |
